Phibro announces planned CEO transition for 2026
Jack Bendheim, who joined Phibro in 1969, will continue to serve as chairman of the board and provide strategic oversight in his new executive chairman role.
USA – Phibro Animal Health Corporation has announced a planned leadership transition that will see long-serving chief executive Jack Bendheim step into the role of executive chairman, while Daniel (Dani) Bendheim assumes the positions of chief executive officer and president, effective July 1, 2026.
The transition, disclosed in a company statement issued on December 18, 2025, is intended to support Phibro’s continued growth and long-term strategic direction.
The US-based animal health and mineral nutrition company, headquartered in Teaneck, New Jersey, supplies antibacterials, anticoccidials, anthelmintics, vaccines and nutritional products to livestock producers worldwide.
Jack Bendheim, who joined Phibro in 1969, has served as president since 1988 and chief executive officer since March 2014.
Under his leadership, the company expanded its global footprint, broadened its product portfolio and strengthened its position as a trusted partner in animal health and nutrition.
Following the transition, he will continue to serve as chairman of the board and provide strategic oversight in his new executive chairman role.
“As Phibro continues to evolve and expand, this is the right moment to transition leadership to guide the company’s next chapter,” Jack Bendheim said.
“Dani brings deep knowledge of our business, strong operational discipline and a global perspective that aligns with the future of our industry.”
Succession rooted in continuity
Dani Bendheim joined Phibro in 1997 and has held a range of senior leadership roles over nearly three decades, including vice president of business development, president of performance products and executive vice president of corporate strategy.
Most recently, he has served as chief transformation officer, leading the Phibro Forward initiative, an enterprise-wide programme focused on improving efficiency, driving growth and strengthening organisational culture.
Phibro said his appointment reflects disciplined succession planning and a commitment to continuity, innovation and growth.
The company’s full executive leadership team will remain in place, and the board of directors has expressed unanimous support for the transition.
“I am honored to take on this role and grateful for my father’s decades of leadership and guidance,” Dani Bendheim said. “Phibro is in the best position it has ever been, a customer-focused company with a strong foundation and commitment to innovation.”
Financial momentum underpins change
The leadership announcement comes against a backdrop of strong financial performance. Phibro, which is currently valued at approximately US$1.65 billion, has delivered a 93.94% share price return over the past year.
According to market data, the company achieved a compound annual revenue growth rate of around 10% over the past five years, with revenue rising by more than 33% in the last twelve months.
In its first quarter of fiscal year 2026, Phibro reported earnings per share of US$0.73, surpassing analyst expectations of US$0.60, while revenue reached US$363.9 million, ahead of forecasts of US$345.44 million.
Analysts have cited strong protein demand, improved profitability in the livestock segment and lower feed and grain input costs as factors supporting the company’s market position.
Sign up HERE to receive our email newsletters with the latest news updates and insights from Africa and the World, and follow us on our WhatsApp channel for updates.
Be the first to leave a comment